Castle Biosciences Inc (CSTL) Financial Statements
Industry: Medical Laboratories (Services)
In fiscal 2025, Castle Biosciences reported revenue of $344.2M, up 3.7% from $332.1M the year before. Net income was -$24.2M (a -7.0% net margin), or -$0.83 per diluted share. Gross margin was 79.4% and operating margin was -12.4%. Operating activities generated $64.3M of cash, leaving $28.3M of free cash flow. At fiscal year end, Castle Biosciences held $578.6M in total assets against $107.7M in total liabilities, including $116.7M of cash and equivalents.
Open the full interactive Castle Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Castle Biosciences Key Stats
| Share Price | $32.88 |
|---|---|
| Market Cap | $999.5M |
| Revenue YoY Growth | +3.7% |
| 52-Week Range | $18.15 – $43.04 |
| Shares Outstanding | 30.4 million (basic, 2026 Q2) |
Castle Biosciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $62.6M | $94.1M | $137.0M | $219.8M | $332.1M | $344.2M |
| Cost of Goods Sold | $9.7M | $15.8M | — | — | — | — |
| Gross Profit | $53.0M | $78.3M | $105.0M | $174.8M | $271.9M | $273.2M |
| Operating Income | -$6.5M | -$40.1M | -$72.9M | -$68.0M | $8.7M | -$42.8M |
| Pre-Tax Income | -$10.2M | -$40.0M | -$68.9M | -$57.4M | $21.6M | -$29.5M |
| Income Tax | $84,000 | -$8.7M | -$1.8M | $101,000 | $3.3M | -$5.4M |
| Net Income | -$10.3M | -$31.3M | -$67.1M | -$57.5M | $18.2M | -$24.2M |
| Diluted EPS | -$0.54 | -$1.24 | -$2.58 | -$2.14 | $0.62 | -$0.83 |
Castle Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $83.0M | $87.0M | $83.7M | $103.5M |
| Net Income | -$501,000 | -$2.3M | -$14.5M | -$2.1M |
| Diluted EPS | -$0.02 | -$0.08 | -$0.49 | -$0.07 |
Castle Biosciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $409.9M | $329.6M | $122.9M | $98.8M | $119.7M | $116.7M |
| Current Assets | $429.6M | $353.7M | $292.3M | $295.6M | $360.2M | $361.1M |
| Total Assets | $439.3M | $462.6M | $447.3M | $453.3M | $531.2M | $578.6M |
| Current Liabilities | $20.9M | $24.9M | $36.1M | $47.7M | $49.4M | $68.7M |
| Total Long-Term Debt | — | — | — | — | $10.0M | $10.1M |
| Total Liabilities | $23.6M | $50.8M | $48.2M | $62.1M | $75.4M | $107.7M |
| Shareholders' Equity | $415.7M | $411.7M | $399.1M | $391.3M | $455.8M | $470.9M |
Castle Biosciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $9.9M | -$19.0M | -$41.7M | -$5.6M | $64.9M | $64.3M |
| Cash From Investing | -$4.7M | -$66.7M | -$166.5M | -$16.2M | -$50.1M | -$60.4M |
| Cash From Financing | $305.9M | $5.4M | $1.5M | -$2.3M | $6.1M | -$7.0M |
| Free Cash Flow | $5.1M | -$22.5M | -$47.3M | -$19.2M | $36.5M | $28.3M |
Figures from Castle Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Castle Biosciences financials page for every line item.
Castle Biosciences Company Profile
| Ticker | CSTL |
|---|---|
| Exchange | Nasdaq |
| Industry | Medical Laboratories (Services) |
| Headquarters | Friendswood, Texas |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer |
| SEC CIK | 0001447362 |
Frequently Asked Questions
What was Castle Biosciences' revenue in fiscal 2025?
Castle Biosciences (CSTL) reported revenue of $344.2M for fiscal 2025.
What is Castle Biosciences' annual revenue history?
Castle Biosciences' annual revenue by fiscal year: 2020: $62.6M; 2021: $94.1M; 2022: $137.0M; 2023: $219.8M; 2024: $332.1M; 2025: $344.2M.
What was Castle Biosciences' net income in fiscal 2025?
Castle Biosciences reported net income of -$24.2M for fiscal 2025.
What was Castle Biosciences' earnings per share (EPS) in fiscal 2025?
Castle Biosciences' diluted EPS was -$0.83 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Castle Biosciences generate in fiscal 2025?
Castle Biosciences generated $28.3M of free cash flow in fiscal 2025.
What was Castle Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Castle Biosciences reported revenue of $103.5M.
How much debt does Castle Biosciences have?
Castle Biosciences reported $10.1M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Castle Biosciences are outstanding?
Castle Biosciences reported a weighted average of 30.4 million basic shares outstanding in 2026 Q2.
What is Castle Biosciences' market cap?
Based on its latest closing price, Castle Biosciences (CSTL) has a market capitalization of about $999.5M.
When does Castle Biosciences' fiscal year end?
Castle Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Castle Biosciences headquartered?
Castle Biosciences lists its business address in Friendswood, Texas in its SEC filings.